Sb 204741

Not available outside of the UK & Ireland.

Application

SB 204741 has been used as a 5-hydroxytryptamine receptor 2B (Htr2B) antagonist: to inhibit Htr2b signaling to test its effect on hepatic stellate cell (HSC) activation in three-month-old adult zebrafishto test its effect on the inhibition of fluoxetine effects in depressive-like behavioral studies in miceto test its effect in reducing scratching behavior evoked by sertraline in mice

Biochem/physiol Actions

5-HT_2B serotonin receptor antagonist.

SB 204741 reduces the synaptic facilitation induced by the low dose of buprenorphine in spinal C-fiber synapses.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

10, 50 mg in glass bottle